3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Lymphoma
155
Leukemia
127
Precursor Cell Lymphoblastic Leukemia-Lymphoma
92
Lymphoma, Non-Hodgkin
81
Leukemia, Myeloid, Acute
80
Lymphoma, Large B-Cell, Diffuse
75
Multiple Myeloma
71
Lymphoma, Follicular
64
Hodgkin Disease
64
Breast Neoplasms
64
Leukemia, Lymphocytic, Chronic, B-Cell
63
Lymphoma, Mantle-Cell
62
Burkitt Lymphoma
60
Myelodysplastic Syndromes
55
Lymphoma, Large-Cell, Immunoblastic
53
Sarcoma
41
Lymphoma, B-Cell, Marginal Zone
40
Neuroblastoma
37
Central Nervous System Neoplasms
34
Neoplasms, Plasma Cell
32
Leukemia, Myeloid, Chronic-Phase
32
Ovarian Neoplasms
31
Leukemia, Myeloid, Accelerated Phase
30
Myeloproliferative Disorders
28
Dendritic Cell Sarcoma, Interdigitating
28
Recurrence
27
Congenital Abnormalities
27
Blast Crisis
26
Neutropenia
24
Anemia, Refractory, with Excess of Blasts
22
Interventions
Rituximab
4
Valganciclovir
2
Valacyclovir
2
Carboplatin
2
Acyclovir
2
valomaciclovir
1
threonic acid
1
otelixizumab
1
cc-486
1
Zidovudine
1
Vincristine
1
Vaccines
1
Tomography, X-Ray Computed
1
Prednisone
1
Polymerase Chain Reaction
1
Methotrexate
1
Matrix-M
1
Magnesium Sulfate
1
MVA vaccine
1
Leucovorin
1
Kidney Transplantation
1
Interferons
1
In Situ Hybridization
1
Immunohistochemistry
1
Granulocyte Colony-Stimulating Factor
1
Gene-Eden-VIR
1
Gastrectomy
1
Flow Cytometry
1
Filgrastim
1
Etoposide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Epstein-Barr Virus Infections
×
Filgrastim
×
Clear all
NCT00953420
2017-08-18
CADEN
Baylor College of Medicine
Phase 2
Completed
20 enrolled